Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

BACKGROUND: Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist for the preventive treatment of migraine. METHODS: In the double-blind, phase 3 ADVANCE trial, participants with 4–14 migraine days/month were randomized to atogepant 10 mg, 30 mg, 60 mg, or placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwedt, Todd J, Lipton, Richard B, Ailani, Jessica, Silberstein, Stephen D, Tassorelli, Cristina, Guo, Hua, Lu, Kaifeng, Dabruzzo, Brett, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739573/
https://www.ncbi.nlm.nih.gov/pubmed/34521260
http://dx.doi.org/10.1177/03331024211042385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739573/
https://www.ncbi.nlm.nih.gov/pubmed/34521260
http://dx.doi.org/10.1177/03331024211042385

Ejemplares similares